Cloudbreak Pharma Inc. (HKG:2592)

Cloudbreak Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	10	-	-
Gross Profit	10	-	-
Selling, General & Admin	9.49	11.28	8.91
Research & Development	37.95	27.49	15.29
Other Operating Expenses	-0.21	-0.89	-0.52
Operating Expenses	47.22	37.88	23.69
Operating Income	-37.22	-37.88	-23.69
Interest Expense	-0.03	-0.28	-0.03
Interest & Investment Income	2.03	3.87	1.6
Currency Exchange Gain (Loss)	0.65	0.66	0.62
Other Non Operating Income (Expenses)	-63.72	-95.78	-45.31
EBT Excluding Unusual Items	-98.3	-129.4	-66.81
Gain (Loss) on Sale of Investments	-	-	0.06
Gain (Loss) on Sale of Assets	-	-	-0
Pretax Income	-98.3	-129.4	-66.76
Income Tax Expense	0.83	0.02	0.08
Net Income	-99.13	-129.42	-66.84
Net Income to Common	-99.13	-129.42	-66.84
Shares Outstanding (Basic)	475	463	459
Shares Outstanding (Diluted)	475	463	459
Shares Change (YoY)	2.78%	0.86%	-
EPS (Basic)	-0.21	-0.28	-0.15
EPS (Diluted)	-0.21	-0.28	-0.15
Free Cash Flow	-26.68	-23.06	-20.83
Free Cash Flow Per Share	-0.06	-0.05	-0.04
Gross Margin	100.00%	-	-
Operating Margin	-372.23%	-	-
Profit Margin	-991.30%	-	-
Free Cash Flow Margin	-266.77%	-	-
EBITDA	-36.35	-37.38	-23.55
D&A For EBITDA	0.87	0.5	0.14
EBIT	-37.22	-37.88	-23.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.